What is Mesothelioma Lung Cancer Phase 3 Study Vorinostat?

Category: Others

false

See also: Clinical Trial

NCT00128102 is a randomized, double-blind, placebo-controlled trial of oral suberoylanilide hydroxamic acid (Vorinostat, MK-0683) in patients with advanced malignant pleural mesothelioma previously treated with systemic chemotherapy. Other study name is MK-0683-014, 2005_010.

Last updated:
There are no evaluations for Mesothelioma Lung Cancer Phase 3 Study Vorinostat.